Yuhan Corporation to Receive $60 Million in Royalties LECLAZA

Yuhan Corporation announced on the 11th that it will receive $60 million (approximately 80 billion KRW) in commercialization royalties for its non-small cell lung cancer treatment "lazertinib" (marketed in Korea as LECLAZA), which was licensed out to Janssen Biotech.

This milestone payment follows the commercialization of the combination therapy of Yuhan's lazertinib and Janssen Biotech's bispecific antibody "amivantamab" (marketed as Rybrevant). Janssen’s parent company, Johnson & Johnson (J&J), received approval from the U.S. Food and Drug Administration (FDA) for the combination therapy on August 20th and is preparing for product launch.

The milestone payment of $60 million amounts to more than 2.5% of Yuhan's total consolidated sales from last year, which were 1.859 trillion KRW. The payment is expected to be received within 60 days.

Yuhan Corporation commented, "This achievement marks an important milestone that validates our ongoing global R&D strategy and our innovative efforts in developing cancer treatments. We plan to continue accelerating the commercialization of lazertinib combination therapy and further research and development in collaboration with Janssen."